NCT02064725 - Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

January 31, 2018

Study Completion Date

July 31, 2018

Conditions

Recurrent or Persistent Endometrial Carcinoma

Interventions

DRUG

Sodium cridanimod

Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).

Trial Locations (21)

10461

Montefiore Medical Center, The Bronx

48201

Barbara Ann Karmanos Cancer Institute, Detroit

95124

Physicians Research Group, San Jose

95403

St. Jude Hospital Yorba Linda, St. Joseph's Heritage Healthcare, Santa Rosa

Unknown

Brest Regional Clinical Hospital, Brest

Minsk City Clinical Oncology Dispensary, Minsk

N.N. Alexandrov National Cancer Centre of Belarus, Minsk

Vitebsk Regional Clinical Oncology Dispensary, Vitebsk

Masaryk Memorial Cancer Institute, Brno

University Hospital Hradec Kralove, Hradec Králové

University Hospital Olomouc, Oncology, Olomouc

Oncology Institute of Saint Alzbeta, Bratislava

Poko Poprad, s.r.o., Poprad

University Hospital Trencin, Trenčín

Cherkasy Regional Oncology Dispensary, Cherkasy

Municipal Institution of Dnipropetrovsk Regional Rada, Dnipropetrovsk

Kharkiv Regional Clinical Oncology Center, Kharkiv

S.P. Grigoryeva Institute of Medical Radiology, Kharkiv

Kherson Regional Oncological Dispensary, Kherson

Sumy State University, Sumy

Vinnitsa Regional Clinical Oncology Center, Vinnitsa